About me
Dr. Matthew Klein is CEO or PTC Therapeutics, a global biopharmaceutical company that discovers, develops and commercializes innovative therapies for rare disorders. Dr. Klein completed his undergraduate degree at the University of Pennsylvania graduating summa cum laude and Phi Beta Kappa. He received his MD degree with honors from Yale University. Prior to beginning a career in the biotech industry, Dr. Klein was the inaugural Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. Prior to joining PTC, Dr. Klein was CEO and Chief Medical Officer of BioElectron. At PTC, Dr. Klein has previously served as Chief Development Officer and Chief Operating Officer before being named CEO in 2023.
